Pfizer (NYSE:PFE) PT Set at $47.00 by The Goldman Sachs Group

Pfizer (NYSE:PFEGet Rating) received a $47.00 price target from investment analysts at The Goldman Sachs Group in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The Goldman Sachs Group’s price objective indicates a potential upside of 0.60% from the stock’s previous close.

PFE has been the topic of a number of other reports. Berenberg Bank set a $44.00 target price on shares of Pfizer in a research note on Wednesday, September 14th. SVB Leerink boosted their price target on shares of Pfizer from $48.00 to $49.00 and gave the company a “market perform” rating in a research report on Thursday, November 3rd. Morgan Stanley boosted their price target on shares of Pfizer from $50.00 to $51.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 2nd. UBS Group set a $55.00 price target on shares of Pfizer in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. set a $50.00 price target on shares of Pfizer in a research report on Tuesday, November 1st. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $56.44.

Pfizer Stock Down 1.3 %

PFE opened at $46.72 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39. The stock has a market cap of $262.21 billion, a price-to-earnings ratio of 8.98, a PEG ratio of 0.59 and a beta of 0.69. Pfizer has a twelve month low of $41.44 and a twelve month high of $61.71. The company’s 50-day moving average price is $45.11 and its two-hundred day moving average price is $48.56.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Pfizer by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock worth $24,801,210,000 after buying an additional 13,790,348 shares during the last quarter. State Street Corp boosted its stake in shares of Pfizer by 0.7% in the 1st quarter. State Street Corp now owns 286,854,205 shares of the biopharmaceutical company’s stock valued at $14,850,442,000 after purchasing an additional 2,037,373 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Pfizer by 0.7% in the 2nd quarter. Northern Trust Corp now owns 66,978,348 shares of the biopharmaceutical company’s stock valued at $3,511,675,000 after purchasing an additional 467,468 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 13.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock valued at $3,097,341,000 after purchasing an additional 6,972,650 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 28.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock valued at $2,246,359,000 after purchasing an additional 9,537,621 shares in the last quarter. Institutional investors own 67.90% of the company’s stock.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.